| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $15,675,231 | 49 | 100 |
| Thoma Jeanne | director | 0 | $0 | 1 | $71,530 | $-71,530 |
| TANNENBAUM RENEE P | director | 0 | $0 | 1 | $146,070 | $-146,070 |
| HAUGHEY THOMAS | director | 0 | $0 | 1 | $161,760 | $-161,760 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 0 | $0 | 2 | $393,828 | $-393,828 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 0 | $0 | 12 | $454,631 | $-454,631 |
| Gutwerg Ori | SVP, GENERICS | 0 | $0 | 3 | $621,438 | $-621,438 |
| Davis Krista | SVP, CHIEF HR OFFICER | 0 | $0 | 5 | $918,622 | $-918,622 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 0 | $0 | 2 | $1.31M | $-1.31M |
| Mutz Christopher | HEAD OF RARE DISEASE | 0 | $0 | 6 | $1.64M | $-1.64M |
| CAREY STEPHEN P. | SVP & CFO | 0 | $0 | 8 | $2.2M | $-2.2M |
| Walsh Patrick D | director | 0 | $0 | 4 | $2.32M | $-2.32M |
| Lalwani Nikhil | PRESIDENT & CEO | 0 | $0 | 4 | $5.44M | $-5.44M |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, …
Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $15.68M worth of ANI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $891,448 and sold $28.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $138,794 was made by Walsh Patrick D () on 2022‑03‑21.
| 2026-10-29 | Sale | CAREY STEPHEN P. | SVP & CFO | 2,850 0.0124% | $72.87 | $207,680 | -1.59% | |
| 2026-10-15 | Sale | Lalwani Nikhil | PRESIDENT & CEO | 5,400 0.0234% | $71.89 | $388,206 | +0.01% | |
| 2026-10-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0023% | $73.59 | $36,795 | +2.03% | |
| 2026-09-29 | Sale | CAREY STEPHEN P. | SVP & CFO | 2,850 0.0126% | $73.00 | $208,050 | -0.47% | |
| 2026-09-15 | Sale | Lalwani Nikhil | PRESIDENT & CEO | 5,400 0.0234% | $71.00 | $383,400 | +0.69% | |
| 2026-09-14 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0024% | $70.79 | $35,395 | +3.13% | |
| 2026-09-11 | Sale | Thoma Jeanne | director | 1,000 0.0048% | $71.53 | $71,530 | +3.43% | |
| 2026-08-31 | Sale | CAREY STEPHEN P. | SVP & CFO | 2,850 0.0134% | $72.80 | $207,480 | -1.31% | |
| 2026-08-25 | Sale | Lalwani Nikhil | PRESIDENT & CEO | 5,400 0.0233% | $74.30 | $401,220 | -4.06% | |
| 2026-08-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0022% | $75.48 | $37,740 | -2.84% | |
| 2026-08-10 | Sale | Gutwerg Ori | SVP, GENERICS | 3,162 0.0152% | $77.00 | $243,474 | -3.97% | |
| 2026-07-29 | Sale | CAREY STEPHEN P. | SVP & CFO | 2,850 0.0125% | $81.36 | $231,876 | -10.49% | |
| 2026-07-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0022% | $81.84 | $40,920 | -8.80% | |
| 2026-07-02 | Sale | CAREY STEPHEN P. | SVP & CFO | 3,313 0.0146% | $86.00 | $284,918 | -13.63% | |
| 2026-06-29 | Sale | CAREY STEPHEN P. | SVP & CFO | 2,850 0.0125% | $84.12 | $239,742 | -11.40% | |
| 2026-06-12 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0022% | $82.03 | $41,015 | -7.75% | |
| 2026-06-08 | Sale | HAUGHEY THOMAS | director | 2,000 0.0089% | $80.88 | $161,760 | -5.59% | |
| 2026-06-05 | Sale | CAREY STEPHEN P. | SVP & CFO | 3,312 0.0144% | $80.00 | $264,960 | -6.66% | |
| 2026-05-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0022% | $78.16 | $39,080 | -4.68% | |
| 2026-05-13 | Sale | Walsh Patrick D | director | 10,000 0.0446% | $80.63 | $806,300 | -4.68% |
| Lalwani Nikhil | PRESIDENT & CEO | 333689 1.4534% | $24.12M | 1 | 11 | +31.46% |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 158490 0.6903% | $11.46M | 1 | 13 | +29.72% |
| HAUGHEY THOMAS | director | 38878 0.1693% | $2.81M | 4 | 2 | <0.0001% |
| Walsh Patrick D | director | 38432 0.1674% | $2.78M | 4 | 5 | +15.33% |
| Thoma Jeanne | director | 26762 0.1166% | $1.93M | 1 | 2 | <0.0001% |
| MORGENSTERN VICTOR A | director | 455571 1.9842% | $32.93M | 2 | 0 | +243.13% |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 431920 1.8812% | $31.22M | 1 | 61 | +24.75% |
| EDELMAN JOSEPH | 10 percent owner | 209100 0.9107% | $15.11M | 23 | 7 | <0.0001% |
| PRZYBYL ARTHUR | President and CEO | 202589 0.8824% | $14.64M | 2 | 10 | +64.77% |
| SIMES STEPHEN M | Vice Chairman, President & CEO | 202167 0.8805% | $14.61M | 4 | 1 | +6.23% |
| HOLUBOW FRED | director | 61259 0.2668% | $4.43M | 1 | 2 | |
| SULLIVAN LOUIS W | director | 47898 0.2086% | $3.46M | 2 | 0 | |
| DONENBERG PHILIP B | Sr. VP of Finance, CFO & Secy | 44322 0.193% | $3.2M | 8 | 0 | +32.33% |
| KJAER PETER | director | 34425 0.1499% | $2.49M | 2 | 0 | +3.25% |
| MANGANO ROSS J | director | 26914 0.1172% | $1.95M | 19 | 0 | +73.75% |
| Pera Antonio R | director | 22660 0.0987% | $1.64M | 1 | 4 | <0.0001% |
| ROSENOW EDWARD C III | director | 20540 0.0895% | $1.48M | 1 | 0 | |
| NASH DAVID | director | 5236 0.0228% | $378,458.08 | 1 | 0 | <0.0001% |
| LEHMAN LEAH M | VP, Product Development | 0 0% | $0 | 1 | 5 |
$1,279,728,023 | 131 | 10.76% | $3.05B | |
$25,613,591 | 65 | -3.30% | $12.27B | |
ANI Pharmaceuticals, Inc. (ANIP) | $14,599,168 | 59 | 12.79% | $1.66B |
$102,709,455 | 46 | 30.55% | $1.45B | |
$73,762,556 | 45 | -9.99% | $2.17B |
| Increased Positions | 163 | +59.71% | 4M | +20.95% |
| Decreased Positions | 114 | -41.76% | 3M | -16.85% |
| New Positions | 49 | New | 534,784 | New |
| Sold Out Positions | 35 | Sold Out | 1M | Sold Out |
| Total Postitions | 322 | +17.95% | 21M | +4.1% |
| Blackrock, Inc. | $199,910.00 | 11.59% | 2.55M | -31,645 | -1.23% | 2025-09-30 |
| Vanguard Group Inc | $100,192.00 | 5.81% | 1.28M | +116 | +<0.01% | 2025-09-30 |
| State Street Corp | $55,819.00 | 3.24% | 711,708 | -4,409 | -0.62% | 2025-09-30 |
| Global Alpha Capital Management Ltd. | $49,457.00 | 2.87% | 630,590 | -231,500 | -26.85% | 2025-09-30 |
| Ubs Group Ag | $46,264.00 | 2.68% | 589,874 | +185,172 | +45.76% | 2025-09-30 |
| Citadel Advisors Llc | $45,496.00 | 2.64% | 580,085 | +10,455 | +1.83% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $39,641.00 | 2.3% | 505,428 | -48,465 | -8.75% | 2025-09-30 |
| Geode Capital Management, Llc | $35,922.00 | 2.08% | 458,014 | +30,468 | +7.13% | 2025-09-30 |
| Deep Track Capital, Lp | $35,294.00 | 2.05% | 450,000 | -250,000 | -35.71% | 2025-09-30 |
| Point72 Asset Management, L.P. | $31,301.00 | 1.81% | 399,092 | +399,092 | New | 2025-09-30 |